These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24151362)

  • 1. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
    Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
    Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.
    Dekker TJ; Borg ST; Hooijer GK; Meijer SL; Wesseling J; Boers JE; Schuuring E; Bart J; van Gorp J; Mesker WE; Kroep JR; Smit VT; van de Vijver MJ
    Breast Cancer Res; 2012 Jun; 14(3):R93. PubMed ID: 22694844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
    Boers JE; Meeuwissen H; Methorst N
    Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
    Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
    Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
    Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
    Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
    Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study.
    Gasljevic G; Lamovec J; Contreras JA; Zadnik V; Blas M; Gasparov S
    Pathol Oncol Res; 2013 Oct; 19(4):855-65. PubMed ID: 23800891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
    Navarro Sanchez JM; Finkelman BS; Tyburski H; Turner BM; Moisini I; Katerji H; Varghese S; Wang X; Schiffhauer LM; Chen JJ; Hicks DG; Zhang H
    Hum Pathol; 2024 Jun; 148():51-59. PubMed ID: 38740270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
    van der Vegt B; de Bock GH; Bart J; Zwartjes NG; Wesseling J
    Mod Pathol; 2009 Jul; 22(7):879-86. PubMed ID: 19305385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
    Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone.
    Layfield LJ; Frazier S; Esebua M; Schmidt RL
    Pathol Res Pract; 2016 Mar; 212(3):190-5. PubMed ID: 26839158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
    Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
    Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of HER2 immunohistochemical results for advanced gastric cancer obtained on using 3 different antibodies].
    Abe M; Tsuchiya K; Yanagawa N; Ogata SY; Nomura T; Fukushima N; Tamura G
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):755-9. PubMed ID: 23863652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas.
    Song Z; Deng Y; Zhuang K; Li A; Liu S
    Int J Clin Exp Pathol; 2014; 7(7):4454-60. PubMed ID: 25120833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.